MedTrace Logo

Dietary Management of Well Nourished Children With Persistent Diarrhea and Secondary Lactose Intolerance With Different Feeding Formulas.( Hospital-Originated Modified Feeding HOMF)

NCT07114796 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2025-08-24

No results posted yet for this study

Summary

Interventional, treatment based study randomized control trial 32O Well nourished children allocated in 2 groups 160 each group ,Group A on lactose free commercial formula already in use,Group B ,ON Rice based feeding recipe .

Conditions

  • Ell-nourished Pediatric Patients
  • Nutritional Management in Diarrhea

Interventions

DIETARY_SUPPLEMENT

Standard Commercial Lactose-Free Formula

"COMMERCIAL LACTOSE FREE FORMULAS" Intervention Type: Dietary Supplement or Nutritional Intervention Name of Intervention: Standard Commercial Lactose-Free Formula Description: A commercially available lactose-free formula (e.g., Isomil, Alfamino, or equivalent), used for feeding children during the stabilization phase of persistent diarrhea treatment. Route: Oral/Nasogastric Dosage: 130 ml/kg/day as per WHO schedule Duration: 7 days

DIETARY_SUPPLEMENT

Rice based recipe method feeding formula

Rice based recipe method feeding formula" Intervention Type: Dietary Supplement or Nutritional Intervention Name of Intervention: Rice-Based Lactose-Free Therapeutic Formula Description: A locally prepared rice-based formula developed as an alternative to F-75, using puffed rice, sugar, oil, and micronutrient mix. It is lactose-free and used for feeding well-nourished children with persistent diarrhea. Route: Oral/Nasogastric Dosage: As per WHO feeding schedule - 130 ml/kg/day in 2-hourly feeds. Duration: 7 days during the stabilization phase For Arm: "COMMERCIAL LACTOSE FREE FORMULAS" Intervention Type: Dietary Supplement or Nutritional Intervention Name of Intervention: Standard Commercial Lactose-Free Formula Description: A commercially available lactose-free formula (e.g., Isomil, Alfamino, or equivalent), used for feeding children during the stabilization phase of persistent diarrhea treatment. Route: Oral/Nasogastric Dosage: 130 ml/kg/day as per WHO schedule Duration:

Sponsors & Collaborators

  • Children's Hospital and Institute of Child Health, Multan

    lead OTHER_GOV

Principal Investigators

  • Muhammad T Sultan, Phd · Bahuddin Zakariya University,Multan.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
59 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2025-06-01
Completion
2025-06-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07114796 on ClinicalTrials.gov